Hemodialysis https://greenmedinfo.com/category/keywords/Hemodialysis en Acupressure is a safe and well-tolerated therapy in adult hemodialysis patients. https://greenmedinfo.com/article/acupressure-safe-and-well-tolerated-therapy-adult-hemodialysis-patients n/a PMID:  Evid Based Complement Alternat Med. 2017 ;2017:7570352. Epub 2017 Feb 21. PMID: 28316636 Abstract Title:  The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. Abstract:  Objectives. To compare the effectiveness of real acupressure versus sham acupressure therapy in improving sleep quality in patients receiving hemodialysis (HD) or hemodiafiltration (HDF). Methods. A multicenter, single-blind, randomized controlled trial was conducted in two Australian dialysis units located in Princess Alexandra Hospital and Logan Hospital, respectively. Forty-two subjects with self-reported poor sleep quality were randomly assigned to real (n = 21) or sham (n = 21) acupressure therapy delivered thrice weekly for four consecutive weeks during routine dialysis sessions. The primary outcome was the Pittsburgh Sleep Quality Index (PSQI) score measured at week four adjusted for baseline PSQI measurements. Secondary outcomes were quality of life (QOL) (SF-8), adverse events, and patient acceptability (treatment acceptability questionnaire, TAQ). Results. The two groups were comparable on global PSQI scores (difference 0.19, 95% confidence interval [CI] -1.32 to 1.70) and on the subscale scores. Similar results were observed for QOL both in the mental (difference -3.88, 95% CI -8.63 to 0.87) and the physical scores (difference 2.45, 95% CI -1.69 to 6.58). There were no treatment-related adverse events and acupressure was perceived favorably by participants. Conclusion. Acupressure is a safe, well-tolerated, and highly acceptable therapy in adult hemodialysis patients in a Western healthcare setting with uncertain implications for therapeutic efficacy. https://greenmedinfo.com/article/acupressure-safe-and-well-tolerated-therapy-adult-hemodialysis-patients#comments Hemodialysis Kidney Diseases Acupressure Acupressure Hemodialysis Kidney Diseases Human Study Fri, 09 Jun 2017 22:35:05 +0000 greenmedinfo 148974 at https://greenmedinfo.com Daily supplementation with of CoQ10 is safe and results in a reduction in plasma concentrations of F2-isoprostanes, a marker of oxidative stress. https://greenmedinfo.com/article/daily-supplementation-coq10-safe-and-results-reduction-plasma-concentrations-f n/a PMID:  Am J Kidney Dis. 2017 Mar ;69(3):389-399. Epub 2016 Dec 4. PMID: 27927588 Abstract Title:  Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial. Abstract:  BACKGROUND: Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis. STUDY DESIGN: Placebo-controlled, 3-arm, double-blind, randomized, clinical trial. SETTING & PARTICIPANTS: 65 patients undergoing thrice-weekly maintenance hemodialysis. INTERVENTION: Patients were randomly assigned in a 1:1:1 ratio to receive once-daily coenzyme Q10 (CoQ10; 600 or 1,200mg) or matching placebo for 4 months. OUTCOMES: The primary outcome was plasma oxidative stress, defined as plasma concentration of F2-isoprotanes. Secondary outcomes included levels of plasma isofurans, levels of cardiac biomarkers, predialysis blood pressure, and safety/tolerability. MEASUREMENTS: F2-isoprostanes and isofurans were measured as plasma markers of oxidative stress, and N-terminal pro-brain natriuretic peptide and troponin T were measured as cardiac biomarkers at baseline and 1, 2, and 4 months. RESULTS: Of 80 randomly assigned patients, 15 were excluded due to not completing at least 1 postbaseline study visit and 65 were included in the primary intention-to-treat analysis. No treatment-related major adverse events occurred. Daily treatment with 1,200mg, but not 600mg, of CoQ10 significantly reduced plasma F2-isoprostanes concentrations at 4 months compared to placebo (adjusted mean changes of -10.7 [95% CI, -7.1 to -14.3] pg/mL [P<0.001] and -8.3 [95% CI, -5.5 to -11.0] pg/mL [P=0.1], respectively). There were no significant effects of CoQ10 treatment on levels of plasma isofurans, cardiac biomarkers, or predialysis blood pressures. LIMITATIONS: Study not powered to detect small treatment effects; difference in baseline characteristics among randomized groups. CONCLUSIONS: In patients undergoing maintenance hemodialysis, daily supplementation with 1,200mg of CoQ10 is safe and results in a reduction in plasma concentrations of F2-isoprostanes, a marker of oxidative stress. Future studies are needed to determine whether CoQ10 supplementation improves clinical outcomes for patients undergoing maintenance hemodialysis. https://greenmedinfo.com/article/daily-supplementation-coq10-safe-and-results-reduction-plasma-concentrations-f#comments Coenzyme Q10 Hemodialysis Kidney Failure: Chronic Oxidative Stress Antioxidants Antioxidants Coenzyme Q10 Hemodialysis Kidney Failure: Chronic oxidative stress Human Study Tue, 11 Jul 2017 21:30:47 +0000 greenmedinfo 150301 at https://greenmedinfo.com Far infrared therapy may have a beneficial effect on maturity and function of arteriovenous fistulas in hemodialysis patients. https://greenmedinfo.com/article/far-infrared-therapy-may-have-beneficial-effect-maturity-and-function-arteriov n/a PMID:  Ren Fail. 2017 Nov ;39(1):613-622. PMID: 28805538 Abstract Title:  Effects of far infrared therapy on arteriovenous fistulas in hemodialysis patients: a meta-analysis. Abstract:  BACKGROUND: Far infrared (FIR) therapy may have a beneficial effect on maturity and function of arteriovenous fistulas (AVFs) in hemodialysis (HD) patients. Therefore, we performed this pooled analysis to assess the protective effects of FIR therapy in HD patients. METHODS: The randomized controlled trials (RCTs) and quasi-RCTs of FIR therapy for HD patients were searched from multiple databases. Relevant studies were screened according to the predefined inclusion criteria. The meta-analyses were performed using RevMan 5.2 software (The Cochrane Collaboration, Oxford, UK). RESULTS: Meta-analysis showed that FIR therapy could significantly increase the vascular access blood flow level (MD, 81.69 ml/min; 95% CI, 46.17-117.21; p < .001), AVFs diameter level (MD, 0.36 mm; 95% CI, 0.22-0.51; p < .001), and the primary AVFs patency (pooled risk ratio = 1.24; 95% CI, 1.12-1.37, p < .001). In addition, therapy with FIR ray radiation could decrease AVFs occlusion rates (pooled risk ratio = 0.20; 95% CI, 0.08-0.46; p < .001) and the level of needling pain (pooled risk ratio = 0.08; 95% CI, 0.06-0.10, p < .001). CONCLUSIONS: FIR therapy can reduce AVFs occlusion rates and needling pain level, while significantly improve the level of vascular access blood flow, AVFs diameter and the primary AVFs patency. https://greenmedinfo.com/article/far-infrared-therapy-may-have-beneficial-effect-maturity-and-function-arteriov#comments Hemodialysis Thermal Therapy: Far-Infrared Hemodialysis Meta Analysis Thermal Therapy: Far-Infrared Sat, 07 Apr 2018 16:57:29 +0000 greenmedinfo 162352 at https://greenmedinfo.com Rose water noticeably reduces the anxiety of hemodialysis patients. https://greenmedinfo.com/article/rose-water-noticeably-reduces-anxiety-hemodialysis-patients n/a PMID:  Nephrourol Mon. 2016 Sep ;8(5):e38347. Epub 2016 Jul 31. PMID: 27878109 Abstract Title:  The Effect of Aromatherapy on Anxiety in Patients. Abstract:  BACKGROUND: Anxiety is the most common mental disorder in end-stage renal disease patients. The use of aromatherapy as a treatment for anxiety has increased substantially in most countries. OBJECTIVES: This study aimed to investigate the effect of inhaling rose water aromatherapy on anxiety in hemodialysis patients. METHODS: This randomized controlled clinical trial was carried out in the hemodialysis ward of Birjand Vali-Asr hospital on 46 patients who were randomly divided into control and experimental groups. The standard state-trait anxiety inventory of Spielberger was used to investigate the anxiety level of the samples. The experimental group inhaled rose water for 4 weeks, but the control group did not undergo any intervention. At the end of week 2 and week 4, the participants' anxiety was measured, and the results were statistically analyzed. RESULTS: Mean scores of state and trait anxiety in the experimental group before intervention were 47/47± 7/6 and 49/56 ± 13/8, respectively; those after week 4 following the intervention were reduced to 37/1 ± 6/5 and 42/9 ± 10/1; inhalation of rose water fragrance in the experimental group caused a significant decrease (P<0.001) in the state and trait anxiety levels compared with controls (P = 0.43). CONCLUSIONS: According to the present study, rose water noticeably reduces the anxiety of hemodialysis patients. Therefore, inhalation of rose water can improve the patient's emotional and spiritual condition during hemodialysis treatment. https://greenmedinfo.com/article/rose-water-noticeably-reduces-anxiety-hemodialysis-patients#comments Anxiety Hemodialysis Rose Anti-Anxiety Agents Aromatherapy Anti-Anxiety Agents Anxiety Hemodialysis Rose rose oil Rose water Human Study Fri, 02 Dec 2016 01:56:40 +0000 greenmedinfo 139773 at https://greenmedinfo.com